Preparation method and application of ivabradine structural analogue or acid salt thereof

An ivabradine technology with a similar structure, applied in the field of medicine, can solve the problems of complicated operation, long steps, difficult side chain synthesis, etc., and achieve the effects of high yield, simple operation and mild reaction conditions

Pending Publication Date: 2019-07-05
重庆德诚永道医药有限公司 +1
View PDF16 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] This method has long steps, cumbersome operation, relatively difficult synthesis of side chains, and repeated preparation of structural formula (I-3) according to the method disclosed in the patent many times. The product of the first step reaction cannot ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method and application of ivabradine structural analogue or acid salt thereof
  • Preparation method and application of ivabradine structural analogue or acid salt thereof
  • Preparation method and application of ivabradine structural analogue or acid salt thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] The preparation of embodiment 1 formula (I-3) compound

[0056] Add 150ml of N-methylpyrrolidone into a 250ml reaction flask, add 15.0g of ivabradine (ie, the compound of formula (II-1)) and 10.0g of manganese dioxide under stirring, and stir and heat up to 90-100°C for complete reaction. The reaction solution was lowered to room temperature, filtered to obtain a filtrate, 50ml of saturated brine and 100ml of dichloromethane were added to the filtrate, the organic phase was extracted and separated, dried over anhydrous sodium sulfate, and the organic phase was concentrated under reduced pressure to obtain a brown oily concentrate. The concentrate was dissolved in 30ml of tetrahydrofuran, and an appropriate amount of concentrated hydrochloric acid was added dropwise under stirring to form a salt, and an appropriate amount of n-heptane was added to slowly crystallize to obtain a brown solid compound of formula (I-3), with a yield of 58%.

[0057]

Embodiment 2

[0058] The preparation of embodiment 2 formula (I-3) compound

[0059] Add 100ml of acetonitrile to a 250ml reaction flask, add 20.0g of ivabradine, 12.0g of tert-butyl hydroperoxide and 1.2g of ketone iodide while stirring, and heat up to reflux with stirring. The reaction solution was cooled to 40-50°C, concentrated under reduced pressure to remove the organic solvent, then added 50ml of water and 50ml of ethyl acetate, extracted and separated to obtain an organic phase, dried over anhydrous sodium sulfate, added 20ml of methanol, and added dropwise an appropriate amount of Concentrated hydrochloric acid was used to form a salt, and the organic phase was concentrated under reduced pressure to obtain a brown foamy compound, which was beaten with methyl tert-butyl ether to obtain a brown solid compound of formula (I-3), with a yield of 62%.

Embodiment 3

[0060] The preparation of embodiment 3 formula (I-3) compound

[0061] Add 20ml of water and 80ml of 1,4-dioxane into a 250ml reaction bottle, add 18.0g of ivabradine and 9.0g of selenium dioxide under stirring, and stir and heat up until the reflux reaction is complete. The reaction solution was cooled to 50-60°C, concentrated under reduced pressure to remove the organic solvent, then added 50ml of water and 100ml of dichloromethane, extracted and separated to obtain an organic phase, dried over anhydrous sodium sulfate, concentrated under reduced pressure to obtain a brown oily concentrate . The concentrate was dissolved in 20ml of acetone, and an appropriate amount of concentrated hydrochloric acid was added dropwise with stirring to form a salt, and an appropriate amount of n-hexane was added to slowly crystallize to obtain a brown solid compound of formula (I-3), with a yield of 81%. HPLC purity test 99.1%; 1 H-NMR (400MHz, d 6 -DMSO)δ: 10.46(s,1H), 7.08(d,1H), 6.95(s,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a preparation method of an ivabradine structural analogue or acid salt thereof. The preparation method comprises the step that a compound shown in formula (II) and an oxidizingagent are subjected to an oxidizing reaction in a solvent to obtain the ivabradine structural analogue shown in formula (I). The preparation method of the ivabradine structural analogue or acid saltthereof has the advantages that an impurity contrast can be provided for the quality control of ivabradine hydrochloride and security detection of clinical medication, and so that the safe and reliable clinical medication is ensured; the operation is simple and convenient, the reaction conditions are mild, the yield is relatively high, and the high-purity product can be obtained through a one-stepchemical reaction.

Description

technical field [0001] The present invention relates to but not limited to the field of medicine, in particular to but not limited to the preparation method of ivabradine structural analog or its salt and the use as impurity reference substance in quality control. Background technique [0002] Ivabradine hydrochloride (Ivabradine hydrochloride, CAS: 148849-67-6) was developed by the French company Servier (Servier), and was first approved for marketing in Ireland by the European Medicines Agency (EMA) in 2006. Approved for listing in China in 2015, the product name is Kelante TM , the marketed dosage form is tablet (specification: 5mg, 7.5mg), which is clinically suitable for patients with NYHA Ⅱ~Ⅳ chronic heart failure with sinus rhythm and heart rate ≥ 75 beats / min, accompanied by systolic dysfunction, and standard treatment includes Beta-blocker combination therapy, or when beta-blocker therapy is contraindicated or intolerable. The chemical name of ivabradine hydrochl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D223/16
CPCC07D223/16
Inventor 王正林黄钦军王俊杜昌勇梁杰黄波
Owner 重庆德诚永道医药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap